Cancer Therapy: A Role For MAPK Inhibitors Combined With MTORC1 Inhibitors

Researchers identify a previously unrecognized problem faced by mTOR inhibitors when it comes to attacking cancers. Nearly a decade ago, while it was being tested as an immunosuppressive agent to prevent organ rejection in transplant patients, the drug rapamycin was also discovered to have anti-tumor properties. Since then, several rapamycin analogs known as mTOR (mammalian target of rapamycin) inhibitors have been tested in clinical trials for the treatment of various types of cancer.

Read the whole article on Science Daily

More from Science Daily